IS6788A - Sölt af ísóþíasól-4-karboxamíði og notkun þeirra sem efnisþættir gegn offjölgun (proliferation) - Google Patents

Sölt af ísóþíasól-4-karboxamíði og notkun þeirra sem efnisþættir gegn offjölgun (proliferation)

Info

Publication number
IS6788A
IS6788A IS6788A IS6788A IS6788A IS 6788 A IS6788 A IS 6788A IS 6788 A IS6788 A IS 6788A IS 6788 A IS6788 A IS 6788A IS 6788 A IS6788 A IS 6788A
Authority
IS
Iceland
Prior art keywords
isothiazole
carboxamide
proliferation
salts
components
Prior art date
Application number
IS6788A
Other languages
English (en)
Inventor
G. Gant Thomas
Robert Williams Glenn
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS6788A publication Critical patent/IS6788A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IS6788A 2000-11-28 2003-04-14 Sölt af ísóþíasól-4-karboxamíði og notkun þeirra sem efnisþættir gegn offjölgun (proliferation) IS6788A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25351300P 2000-11-28 2000-11-28
PCT/IB2001/002193 WO2002044158A1 (en) 2000-11-28 2001-11-19 Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents

Publications (1)

Publication Number Publication Date
IS6788A true IS6788A (is) 2003-04-14

Family

ID=22960587

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6788A IS6788A (is) 2000-11-28 2003-04-14 Sölt af ísóþíasól-4-karboxamíði og notkun þeirra sem efnisþættir gegn offjölgun (proliferation)

Country Status (50)

Country Link
US (1) US6831091B2 (is)
EP (1) EP1337521B1 (is)
JP (2) JP2004514714A (is)
KR (2) KR20050116401A (is)
CN (1) CN1231474C (is)
AP (1) AP2001002358A0 (is)
AR (1) AR031512A1 (is)
AT (1) ATE340786T1 (is)
AU (2) AU1420402A (is)
BG (1) BG107752A (is)
BR (1) BR0115621A (is)
CA (1) CA2430065C (is)
CR (1) CR6963A (is)
CY (1) CY1106240T1 (is)
CZ (1) CZ20031315A3 (is)
DE (1) DE60123461T2 (is)
DK (1) DK1337521T3 (is)
DO (1) DOP2001000288A (is)
EA (1) EA005859B1 (is)
EC (1) ECSP034628A (is)
EE (1) EE200300247A (is)
ES (1) ES2271086T3 (is)
GE (1) GEP20053652B (is)
GT (1) GT200100237A (is)
HK (1) HK1059085A1 (is)
HN (1) HN2001000268A (is)
HR (1) HRP20030408A2 (is)
HU (1) HUP0302553A3 (is)
IL (1) IL155371A0 (is)
IS (1) IS6788A (is)
MA (1) MA26960A1 (is)
MX (1) MXPA03004714A (is)
MY (1) MY136686A (is)
NO (1) NO325187B1 (is)
NZ (1) NZ525788A (is)
OA (1) OA12532A (is)
PA (1) PA8533801A1 (is)
PE (1) PE20020591A1 (is)
PL (1) PL362079A1 (is)
PT (1) PT1337521E (is)
SI (1) SI1337521T1 (is)
SK (1) SK5862003A3 (is)
SV (1) SV2002000748A (is)
TN (1) TNSN01167A1 (is)
TW (1) TWI287542B (is)
UA (1) UA74221C2 (is)
UY (1) UY27039A1 (is)
WO (1) WO2002044158A1 (is)
YU (1) YU36403A (is)
ZA (1) ZA200303341B (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
WO2004011461A1 (en) * 2002-07-25 2004-02-05 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
ATE502635T1 (de) * 2002-08-19 2011-04-15 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
US20070020704A1 (en) 2003-05-20 2007-01-25 Scott Wilhelm Diaryl ureas with kinase inhibiting activity
BR122016015715B8 (pt) 2003-07-23 2021-05-25 Bayer Healthcare Llc composições farmacêuticas de metilamida de ácido 4[4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenóxi)-piridina-2-carboxílico
RU2317295C1 (ru) * 2003-10-27 2008-02-20 Мерк Энд Ко., Инк. Соль антагониста ccr-2
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
JP2007535565A (ja) 2004-04-30 2007-12-06 バイエル ファーマシューティカルス コーポレーション 癌の治療に有用な置換ピラゾリル尿素誘導体
TW200538104A (en) * 2004-05-17 2005-12-01 Pfizer Prod Inc Phenyl derivatives for the treatment of abnormal cell growth
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN101472906B (zh) 2006-06-16 2012-04-25 H.隆德贝克有限公司 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
EP3696195B1 (en) 2010-07-23 2024-02-14 Trustees of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
KR102433489B1 (ko) * 2013-03-14 2022-08-17 팬옵티카, 인크. 눈의 후안부로의 약물 전달을 위한 안구용 제제
JP6657193B2 (ja) * 2014-09-17 2020-03-04 パンオプティカ，インコーポレイテッド 薬物送達および前眼部保護のための眼用製剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця

Also Published As

Publication number Publication date
CZ20031315A3 (cs) 2004-04-14
HRP20030408A2 (en) 2003-08-31
MXPA03004714A (es) 2003-08-19
SI1337521T1 (sl) 2006-12-31
NO20032388L (no) 2003-07-18
EP1337521B1 (en) 2006-09-27
WO2002044158A1 (en) 2002-06-06
CN1231474C (zh) 2005-12-14
TWI287542B (en) 2007-10-01
MY136686A (en) 2008-11-28
US6831091B2 (en) 2004-12-14
CY1106240T1 (el) 2011-06-08
HN2001000268A (es) 2002-01-30
AU1420402A (en) 2002-06-11
CN1476439A (zh) 2004-02-18
NO20032388D0 (no) 2003-05-27
US20020151573A1 (en) 2002-10-17
NO325187B1 (no) 2008-02-11
DE60123461T2 (de) 2007-02-15
ATE340786T1 (de) 2006-10-15
PE20020591A1 (es) 2002-07-06
IL155371A0 (en) 2003-11-23
BR0115621A (pt) 2003-09-02
ECSP034628A (es) 2003-07-25
GT200100237A (es) 2002-07-03
JP2008056692A (ja) 2008-03-13
GEP20053652B (en) 2005-11-10
OA12532A (en) 2006-06-02
EP1337521A1 (en) 2003-08-27
TNSN01167A1 (fr) 2005-11-10
AU2002214204B2 (en) 2007-05-24
HUP0302553A2 (hu) 2003-11-28
UY27039A1 (es) 2002-07-31
KR20030059275A (ko) 2003-07-07
YU36403A (sh) 2006-08-17
EA200300424A1 (ru) 2003-10-30
DK1337521T3 (da) 2007-01-29
KR20050116401A (ko) 2005-12-12
PT1337521E (pt) 2006-12-29
CR6963A (es) 2003-11-25
EE200300247A (et) 2003-10-15
DE60123461D1 (de) 2006-11-09
CA2430065A1 (en) 2002-06-06
ES2271086T3 (es) 2007-04-16
EA005859B1 (ru) 2005-06-30
HUP0302553A3 (en) 2009-03-30
SK5862003A3 (en) 2004-05-04
PL362079A1 (en) 2004-10-18
BG107752A (bg) 2004-01-30
HK1059085A1 (en) 2004-06-18
JP4971946B2 (ja) 2012-07-11
AP2001002358A0 (en) 2001-12-31
JP2004514714A (ja) 2004-05-20
AR031512A1 (es) 2003-09-24
UA74221C2 (uk) 2005-11-15
PA8533801A1 (es) 2002-10-31
NZ525788A (en) 2004-11-26
ZA200303341B (en) 2004-04-30
CA2430065C (en) 2008-05-20
SV2002000748A (es) 2002-12-02
DOP2001000288A (es) 2002-12-15
MA26960A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
IS6788A (is) Sölt af ísóþíasól-4-karboxamíði og notkun þeirra sem efnisþættir gegn offjölgun (proliferation)
DE60131315D1 (de) Beatmungskreislauf-Komponenten
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
DK1202941T3 (da) Gipssammensætninger og beslægtede fremgangsmåder
DK1438306T3 (da) Derivater af UK-2A
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
DE60215417D1 (de) Netzwerkschaltung
NO20024355L (no) Nukleosidforbindelser og anvendelser derav
IS6000A (is) Ný aralkýlamín af spírófúrópýridínum sem nytsamleg eru í meðferð
DK1360169T3 (da) Succinatsalt af O-desmethyl-venlafaxin
DE60220053D1 (de) Schaltkreis
DK1212317T3 (da) Indolderivater og anvendelse deraf til behandling af osteoporose blandt andre anvendelser
NO20021786L (no) Skumdempningsfremgangsmåter og sammensetninger
IS6786A (is) Samsetning af GABA gerandefnum og sorbitól vetnissviftahindrum
DE60215601D1 (de) Stabile Zusammensetzung
DK1274709T3 (da) Salte af bicykliske, N-acylerede imidazo-3-aminer og imidazo-5-aminer
DE60117938D1 (de) Vorspannen von Bauteilen
DK1337228T3 (da) Sammensætninger til fjernelse af human cerumen
NO20002091D0 (no) Elektronisk auskultasjons-utstyrssett
IS6620A (is) Nýr fjölgervingur V af tórasemíði
DK1372652T3 (da) Kombination af docetaxel og flavopiridol
FI20011778A0 (fi) Ryhmälähetyksen toteutus
DK1441746T3 (da) Sammens tning og fremgangsmode